Abstract
In the last years, molecular docking emerged as a powerful tool to investigate the interactions between opioid ligands and their receptors, thus driving the design and development of new selective agonists or antagonists of therapeutic interest. This review especially covers the most representative and recent comparative molecular docking analyses of structurally related compounds, as well as of agonists and antagonists within the active and inactive states of the receptors. The comparative analyses gave important information on the structural determinants responsible for the affinity and selectivity of the ligands, and defined the features responsible for the activation of the receptors. A special section is dedicated to the analyses of recently discovered, unusual agonists lacking of the tyramine pharmacophore, such as Salvinorin A, and the cyclopeptides which comprise the D-Trp-Phe pharmacophoric motif. For the atypical structure of these compounds, the docking proved to be essential to disclose how they interact with and activate the receptors.
Keywords: Opioid receptors, peptides, morphine, fentanyl, endomorphin, molecular docking, salvinorin, D-Trp-Phe, JOM, conformational analysis, ligand-receptor interactions, GPCR
Current Medicinal Chemistry
Title:Molecular Docking of Opiates and Opioid Peptides, a Tool for the Design of Selective Agonists and Antagonists, and for the Investigation of Atypical Ligand-Receptor Interactions
Volume: 19 Issue: 11
Author(s): L. Gentilucci, A. Tolomelli, R. De Marco and R. Artali
Affiliation:
Keywords: Opioid receptors, peptides, morphine, fentanyl, endomorphin, molecular docking, salvinorin, D-Trp-Phe, JOM, conformational analysis, ligand-receptor interactions, GPCR
Abstract: In the last years, molecular docking emerged as a powerful tool to investigate the interactions between opioid ligands and their receptors, thus driving the design and development of new selective agonists or antagonists of therapeutic interest. This review especially covers the most representative and recent comparative molecular docking analyses of structurally related compounds, as well as of agonists and antagonists within the active and inactive states of the receptors. The comparative analyses gave important information on the structural determinants responsible for the affinity and selectivity of the ligands, and defined the features responsible for the activation of the receptors. A special section is dedicated to the analyses of recently discovered, unusual agonists lacking of the tyramine pharmacophore, such as Salvinorin A, and the cyclopeptides which comprise the D-Trp-Phe pharmacophoric motif. For the atypical structure of these compounds, the docking proved to be essential to disclose how they interact with and activate the receptors.
Export Options
About this article
Cite this article as:
Gentilucci L., Tolomelli A., De Marco R. and Artali R., Molecular Docking of Opiates and Opioid Peptides, a Tool for the Design of Selective Agonists and Antagonists, and for the Investigation of Atypical Ligand-Receptor Interactions, Current Medicinal Chemistry 2012; 19 (11) . https://dx.doi.org/10.2174/092986712799945030
DOI https://dx.doi.org/10.2174/092986712799945030 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ROS1 Kinase Inhibitors for Molecular-Targeted Therapies
Current Medicinal Chemistry A Novel Quinazoline-4-one Derivatives as a Promising Cytokine Inhibitors: Synthesis, Molecular Docking, and Structure-activity Relationship
Current Pharmaceutical Biotechnology 5-HT3 Receptors
Current Drug Targets - CNS & Neurological Disorders Cancer Biomarker Discovery for Precision Medicine: New Progress
Current Medicinal Chemistry Antitumor Potential and Possible Targets of Phenothiazine-Related Compounds
Current Drug Targets Vagotomy and Gastric Tumorigenesis
Current Neuropharmacology Pleural Involvement Due to Metastatic Melanoma: A Rare Complication and Literature Review
Current Respiratory Medicine Reviews Sphingolipids in Inflammation: Roles and Implications
Current Molecular Medicine Nanomedicine: A New Frontier in Cancer Therapeutics
Current Drug Delivery Modified Alginate Beads for Mucoadhesive Drug Delivery System: An Updated Review of Patents
Recent Patents on Drug Delivery & Formulation Aspirin: from a Historical Perspective
Recent Patents on Cardiovascular Drug Discovery Past, Present and Future of Nutrigenomics and its Influence on Drug Development
Current Drug Discovery Technologies Obesity Pharmacotherapy: Current Perspectives and Future Directions
Current Cardiology Reviews Intracellular Signaling Triggered by Formyl-Peptide Receptors in Nonphagocytic Cells
Current Signal Transduction Therapy Herbal Medicines for Diabetes Management and its Secondary Complications
Current Diabetes Reviews Targeting Tyrosine Kinase Receptors in Hepatocellular Carcinoma
Current Cancer Drug Targets The Means to an End of Tumor Cell Resistance to Chemotherapeutic Drugs Targeting Thymidylate Synthase: Shoot the Messenger
Current Drug Targets E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets
Current Cancer Drug Targets Anti-Inflammatory Properties of Drugs from saffron crocus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Lung Cancer Epidemiology - A Global View
Current Respiratory Medicine Reviews